SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target.
Saved in:
| Title: | SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target. |
|---|---|
| Authors: | Krossa I; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Pisibon C; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Cheli Y; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Bille K; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Dalmasso M; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Hamadat S; CNRS UMR9019 Genome Integrity and Cancers, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Inovarion, Paris, 75005, France., Husser C; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Irondelle M; University Côte d'Azur, Nice, France., Cherfils-Vicini J; University Côte d'Azur, Nice, France.; Centre National de la Recherche Scientifique (CNRS) UMR7284, Inserm U1081, Institute for Research on Cancer and Aging, Nice (IRCAN), Nice, 06107, France., Soysouvanh F; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Nahon-Esteve S; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France.; Department of Ophthalmology, Centre Hospitalier Universitaire of Nice, Nice, France., Martel A; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France.; Department of Ophthalmology, Centre Hospitalier Universitaire of Nice, Nice, France., Lassalle S; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France.; Laboratory of Clinical and Experimental Pathology (LPCE), Biobank BB-0033-00025, Nice, France., Caujolle JP; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France.; Department of Ophthalmology, Centre Hospitalier Universitaire of Nice, Nice, France., Maschi C; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France.; Department of Ophthalmology, Centre Hospitalier Universitaire of Nice, Nice, France., Baillif S; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France.; Department of Ophthalmology, Centre Hospitalier Universitaire of Nice, Nice, France., Hasson D; Tisch Cancer Institute Bioinformatics for Next Generation Sequencing (BiNGS) Core, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Carcamo S; Tisch Cancer Institute Bioinformatics for Next Generation Sequencing (BiNGS) Core, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Aplin AE; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA., Davidson I; IGBMC, CNRS UMR7104, INSERM U1258, Université de Strasbourg, Illkirch, France., Bernstein E; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA., Naim V; CNRS UMR9019 Genome Integrity and Cancers, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Ballotti R; University Côte d'Azur, Nice, France.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Bertolotto C; University Côte d'Azur, Nice, France. Corine.Bertolotto@univ-cotedazur.fr.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France. Corine.Bertolotto@univ-cotedazur.fr., Strub T; University Côte d'Azur, Nice, France. thomas.strub@univ-cotedazur.fr.; Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2025 and Equipe labellisée ARC 2022, Centre Méditerranéen de Médecine Moléculaire, Nice, France. thomas.strub@univ-cotedazur.fr. |
| Source: | Cell death & disease [Cell Death Dis] 2025 Oct 24; Vol. 16 (1), pp. 754. Date of Electronic Publication: 2025 Oct 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
